Hangzhou Wutong Tree Pharmaceutical Co., Ltd. has a registered capital of 300 million. Since its establishment on March 14, 2017, it has been committed to the research and development of innovative tumor drugs. The researchers of the university are responsible for the research and development, and the drug innovation model with the participation of governments at all levels and entrepreneurs. At the same time, it has carried out the research and development of more than 8 innovative projects. So far, 4 clinical approvals have been obtained, one of which has successfully achieved a transfer of 48.5 million.